← 返回

放疗与 CAR-T 协同治疗的全身肿瘤消退

英文原题:Systemic tumor regression with synergy therapy: radiotherapy and CAR-T.

查看英文原题

Systemic tumor regression with synergy therapy: radiotherapy and CAR-T.

PubMed 2024/11/22(内容时间) Cell Death Discov Q1 · IF 10.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

胰腺导管腺癌(PDAC)是预后最差的消化道恶性肿瘤之一。近期,靶向CLDN18.2的CAR-T 疗法在PDAC中显示出良好临床效果。放疗作为传统治疗方式,可诱导全身免疫活化和远隔效应;但二者联合治疗PDAC的协同作用及机制仍不清楚。本研究构建了CLDN18.2特异性CAR-T 细胞,并将其用于单侧和双侧小鼠肿瘤模型。结果显示,这种协同疗法不仅增强了单侧荷瘤小鼠的肿瘤杀伤效果,也使双侧肿瘤模型中的局部和远处肿瘤均发生消退。从机制上看,放疗早期诱导的细胞凋亡促进CD8+ T细胞增殖;局部及远处肿瘤部位趋化因子CCL2水平升高,则促进CAR-T 细胞和内源性T细胞浸润,最终产生全身性肿瘤抑制作用。本研究提出了放疗联合CAR-T 治疗转移性胰腺癌这一有前景的方法,阐明了CAR-T 细胞增强放疗效应的体外机制,并指出了对抗转移性胰腺癌的新策略。

展开英文摘要原文

Pancreatic ductal adenocarcinoma (PDAC) is one of the most poorly prognostic digestive tract malignancies. CLDN18. 2 CAR-T therapy has recently shown promising clinical effects in PDAC. Radiotherapy, a traditional treatment, can induce systemic immune activation and abscopal effects.

However, the synergistic effect and mechanism of their combination in PDAC treatment remain poorly understood. In this study, we developed a CLDN18. 2-specific CAR-T and applied it to unilateral and bilateral mouse tumor models.

Our results demonstrated that this synergy therapy not only improved tumor-killing effects in unilateral tumor-bearing mice but also induced regression in both local and distant tumors in bilateral tumor models.

Mechanistically, early radiation-induced apoptosis promoted the proliferation of CD8 + T cells, while increased chemokine CCL2 levels from localized and distant tumor sites facilitated CAR-T and endogenous T cell infiltration, leading to systemic tumor suppression.

This study proposes a promising approach for treating metastatic pancreatic cancer by combining radiotherapy and CAR-T therapy, elucidating the mechanism of CAR-T cell-enhanced radiotherapy effects ex vivo, and highlighting a novel strategy for combating metastatic pancreatic cancer.

论文信息

作者
Ma X、Zhang W、Zeng M、Asavasupreechar T、Kang S、Li Y、Yu L
第一作者单位
Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen Clinical Research Center for hematologic disease, Shenzhen University, Shenzhen, China.China
通讯作者单位
Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen Clinical Research Center for hematologic disease, Shenzhen University, Shenzhen, China. yuli@szu.edu.cn.China
期刊
Cell death discovery2024 Nov 22
原文标识
PubMed 39578426 · DOI 10.1038/s41420-024-02245-3